Dassault Systèmes is reported to be in talks to acquire drug-trial software maker ArisGlobal from Nordic Capital for about $2.0B, per the Financial Times. The deal, if completed, would be a meaningful strategic expansion for Dassault in pharma clinical software. Reported talks suggest a modest positive read-through, but details (terms, timing, approvals) remain uncertain.
Dassault Systèmes is reported to be in talks to acquire drug-trial software maker ArisGlobal from Nordic Capital for about $2.0B, per the Financial Times. The deal, if completed, would be a meaningful strategic expansion for Dassault in pharma clinical software. Reported talks suggest a modest positive read-through, but details (terms, timing, approvals) remain uncertain.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
